+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cardiovascular Drugs Market Research Reports

From
Matrix Metalloproteinase (MMP) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Matrix Metalloproteinase (MMP) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Congenital Heart Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Congenital Heart Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Recurrent Pericarditis - Pipeline Insight, 2025 - Product Thumbnail Image

Recurrent Pericarditis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Coronary Occlusion (Includes CAD Also) - Pipeline Insight, 2025 - Product Thumbnail Image

Coronary Occlusion (Includes CAD Also) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hypoxia - Pipeline Insight, 2025 - Product Thumbnail Image

Hypoxia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Infantile Neuroaxonal Dystrophy - Pipeline Insight, 2025 - Product Thumbnail Image

Infantile Neuroaxonal Dystrophy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Mitral Valve Insufficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Mitral Valve Insufficiency - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Vascular Ehlers-Danlos Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Vascular Ehlers-Danlos Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Pericarditis - Pipeline Insight, 2025 - Product Thumbnail Image

Pericarditis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Vascular Calcification - Pipeline Insight, 2025 - Product Thumbnail Image

Vascular Calcification - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Potassium Channel Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Potassium Channel Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Complement C1 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Complement C1 Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Purinoceptor P2Y12 Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Purinoceptor P2Y12 Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Apolipoprotein C-III Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Apolipoprotein C-III Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
ACE/ARB Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

ACE/ARB Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Angiotensin Type 1 Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Angiotensin Type 1 Receptor Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Cardiovascular Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cardiovascular diseases. These drugs are used to treat conditions such as hypertension, coronary artery disease, congestive heart failure, and arrhythmias. Cardiovascular drugs are also used to reduce the risk of stroke, heart attack, and other cardiovascular events. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. Major players in the market include Pfizer, Merck, Novartis, Sanofi, and Bristol-Myers Squibb. These companies are involved in the research, development, and production of cardiovascular drugs. Additionally, there are a number of smaller companies that specialize in the production of generic cardiovascular drugs. These companies include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more